mechlorethamine has been researched along with Sezary Syndrome in 15 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
Sezary Syndrome: A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the exact frequency and the histological features of cutaneous intolerance to mechlorethamine (CIM) hydrochloride therapy in patients with cutaneous T-cell lymphomas, including Langerhans cell histiocytosis." | 7.70 | A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas. ( Avril, MF; Bagot, M; Beylot-Barry, M; Delaunay, M; Estève, E; Grange, F; Joly, P; Laroche, L; Souteyrand, P; Thomine, E; Vaillant, L; Wechsler, J, 1999) |
| "Complete responses lasting from 4 to 14 years were documented in 65 of 331 (20%) patients with cutaneous T cell lymphoma treated with topical mechlorethamine (HN2) between 1968 and 1982." | 7.67 | Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. ( Kantor, AF; Micaily, B; Shrager, L; Tan, ET; Van Scott, EJ; Vonderheid, EC, 1989) |
| "A group of 243 patients with mycosis fungoides (MF) received treatment with topical applications of dilute aqueous solutions of mechlorethamine and/or systemic chemotherapy over the past 10 years." | 7.66 | A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy. ( Johnson, WC; Van Scott, EJ; Vonderheid, EC; Wallner, PE, 1979) |
| "To study the exact frequency and the histological features of cutaneous intolerance to mechlorethamine (CIM) hydrochloride therapy in patients with cutaneous T-cell lymphomas, including Langerhans cell histiocytosis." | 3.70 | A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas. ( Avril, MF; Bagot, M; Beylot-Barry, M; Delaunay, M; Estève, E; Grange, F; Joly, P; Laroche, L; Souteyrand, P; Thomine, E; Vaillant, L; Wechsler, J, 1999) |
| "Patients with mycosis fungoides (n = 23) or Sézary syndrome (n = 5) were treated with 4 months of recombinant interferon alfa together with isotretinoin, followed by total skin electron beam therapy alone (for stage I to II disease) or preceded by chemotherapy (for stage III to IV disease)." | 3.69 | Combined modality therapy for cutaneous T-cell lymphoma. ( Cabanillas, FF; Duvic, M; Eifel, PJ; Kurzrock, R; Lemak, NA; Redman, JR; Tucker, SL, 1996) |
| "Complete responses lasting from 4 to 14 years were documented in 65 of 331 (20%) patients with cutaneous T cell lymphoma treated with topical mechlorethamine (HN2) between 1968 and 1982." | 3.67 | Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. ( Kantor, AF; Micaily, B; Shrager, L; Tan, ET; Van Scott, EJ; Vonderheid, EC, 1989) |
| "A group of 243 patients with mycosis fungoides (MF) received treatment with topical applications of dilute aqueous solutions of mechlorethamine and/or systemic chemotherapy over the past 10 years." | 3.66 | A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy. ( Johnson, WC; Van Scott, EJ; Vonderheid, EC; Wallner, PE, 1979) |
| "Mycosis fungoides is a cutaneously-derived malignant lymphoma which, without effective treatment, may run an unrelenting, rapidly lethal course." | 1.26 | Mycosis fungoides: clinical and therapeutic review. ( Basler, RS; Lynch, PJ, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (46.67) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jawed, SI | 1 |
| Myskowski, PL | 1 |
| Horwitz, S | 1 |
| Moskowitz, A | 1 |
| Querfeld, C | 1 |
| Parmentier, L | 1 |
| Dürr, C | 1 |
| Vassella, E | 1 |
| Beltraminelli, H | 1 |
| Borradori, L | 1 |
| Haneke, E | 1 |
| Duvic, M | 3 |
| Weinerman, BH | 1 |
| Lu, LC | 1 |
| Gaeke, ME | 1 |
| Variakojis, D | 1 |
| Sweet, DL | 1 |
| Zachariae, H | 1 |
| Bjerring, P | 1 |
| Brodthagen, U | 1 |
| Søgaard, H | 1 |
| Lemak, NA | 1 |
| Redman, JR | 1 |
| Eifel, PJ | 1 |
| Tucker, SL | 1 |
| Cabanillas, FF | 1 |
| Kurzrock, R | 1 |
| Jones, GW | 1 |
| Wilson, LD | 1 |
| Estève, E | 1 |
| Bagot, M | 1 |
| Joly, P | 1 |
| Souteyrand, P | 1 |
| Beylot-Barry, M | 1 |
| Vaillant, L | 1 |
| Delaunay, M | 1 |
| Avril, MF | 1 |
| Laroche, L | 1 |
| Grange, F | 1 |
| Thomine, E | 1 |
| Wechsler, J | 1 |
| Vonderheid, EC | 2 |
| Van Scott, EJ | 2 |
| Wallner, PE | 1 |
| Johnson, WC | 1 |
| Basler, RS | 1 |
| Lynch, PJ | 1 |
| Tan, ET | 1 |
| Kantor, AF | 1 |
| Shrager, L | 1 |
| Micaily, B | 1 |
| Bernengo, MG | 1 |
| Meregalli, M | 1 |
| Jemma, C | 1 |
| Lisa, F | 1 |
| Winkler, CF | 1 |
| Sausville, EA | 1 |
| Ihde, DC | 1 |
| Fischmann, AB | 1 |
| Schechter, GP | 1 |
| Kumar, PP | 1 |
| Nibhanupdi, JR | 1 |
| Minna, JD | 1 |
| Makuch, RW | 1 |
| Eddy, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatments and Outcomes in Patients With Primary Cutaneous Lymphoma: a Nationwide Multi-center Prospective Study in China[NCT05518851] | 3,000 participants (Anticipated) | Observational | 2022-08-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for mechlorethamine and Sezary Syndrome
| Article | Year |
|---|---|
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Combined Modality Therapy; Dermatologic Agents; | 2014 |
Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2007 |
Mycosis fungoides and total skin electron beam radiation.
Topics: Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Disease-Free Survival; Electrons; Humans; | 1997 |
Current treatment of Cutaneous T-Cell Lymphoma.
Topics: Administration, Oral; Administration, Topical; Anticarcinogenic Agents; Apoptosis; Bexarotene; Biops | 2001 |
11 other studies available for mechlorethamine and Sezary Syndrome
| Article | Year |
|---|---|
Specific nail alterations in cutaneous T-cell lymphoma: successful treatment with topical mechlorethamine.
Topics: Administration, Topical; Aged, 80 and over; Gene Rearrangement, T-Lymphocyte; Humans; Lymphocytes; M | 2010 |
Sézary syndrome-an unusual case.
Topics: Administration, Topical; Chlorambucil; Female; Humans; Leukocyte Count; Mechlorethamine; Prednisone; | 1981 |
Mycosis fungoides.
Topics: Adult; Female; Humans; Lymph Nodes; Lymphocytes; Male; Mechlorethamine; Middle Aged; Mycosis Fungoid | 1981 |
Photopheresis in the red man or pre-Sézary syndrome.
Topics: Acitretin; Aged; Dermatitis, Exfoliative; Follow-Up Studies; Humans; Male; Mechlorethamine; Middle A | 1995 |
Combined modality therapy for cutaneous T-cell lymphoma.
Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Ca | 1996 |
A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkyla | 1999 |
A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy.
Topics: Administration, Topical; Adolescent; Adult; Aged; Child; Female; Humans; Male; Mechlorethamine; Midd | 1979 |
Mycosis fungoides: clinical and therapeutic review.
Topics: Humans; Lymphoma; Mechlorethamine; Methoxsalen; Mycosis Fungoides; Photochemotherapy; Sezary Syndrom | 1979 |
Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma.
Topics: Administration, Cutaneous; Age Factors; Aged; Female; Follow-Up Studies; Humans; Lymphoma; Male; Mec | 1989 |
Functional properties in Sézary cells with an unusual phenotype.
Topics: Aged; Antibodies, Monoclonal; Chlorambucil; Dermatitis, Exfoliative; Drug Therapy, Combination; Huma | 1985 |
Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 1986 |